Market research
4XT.F XPhyto Therapeutics Corp
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 32M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.15
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 32M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.15
About
About XPhyto Therapeutics Corp
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4XT.F discussion.
5 years, 5 months ago
XPhyto Therapeutics Corp is currently in a long term downtrend where the price is trading 26.1% below its 200 day moving average.
From a valuation standpoint, the stock is 74.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 338.4.
XPhyto Therapeutics Corp's total revenue rose by 87.7% to $85K since the same quarter in the previous year.
Its net income has dropped by 82.3% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 145.9% to $-3M since the same quarter in the previous year.
Based on the above factors, XPhyto Therapeutics Corp gets an overall score of 2/5.